Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reversal of neuromuscular blockade with sugammadex in end-stage hepatic failure
2009-012763-34Phase 4Terminated
- Sponsor
- Medical University of Vienna
- Start
- Aug 2009
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, single-arm trial of Sugammadex in hepatic failure, sponsored by Medical University of Vienna. Primary endpoint: Time to TOF ratio 0.9. Started Aug 2009; status: terminated.
02
Drugs
Sugammadex
03
Conditions
hepatic failure
Beyond the preview
Go deeper on 2009-012763-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012763-34.